The front line of research and clinical trials
CSI specialises in supplying oncology products to clinical trials all over the world. Treatments for cancer have been advancing at an accelerated pace in recent years, resulting in significant clinical benefits and increased specificity through selection according to biomarkers or through engineered cell or gene therapies. Innovation is in our DNA, and we want to be part of your journey, helping you to advance your studies and improve patient outcomes with our clinical trial supply expertise.
Oncology Products
Oncology product sourcing specialists
CSI has supplied oncology products to more than 700 studies – from generics to the most sophisticated cold chain biologics.
Pembrolizumab
50+
1, 2, 3
Europe, USA
Aflibercept
50+
1, 2, 3
Europe, USA,
Latin America
Nivolumab
50+
1, 2, 3
Global
Ipilimumab
50+
1, 2, 3
Global
Ruxolitinib
25+
2, 3
Global
Biologic
Number of Studies
Phase of Trial
Geography
Keytruda
(pembrolizumab)
50+
1, 2, 3
Europe, USA
Eylea
(aflibercept)
50+
1, 2, 3
Europe, USA,
Latin America
Opdivo
(nivolumab)
50+
1, 2, 3
Global
Yervoy
(ipilimumab)
50+
1, 2, 3
Global
Jakavi
(ruxolitinib)
25+
2, 3
Global
Biologic
Number of Studies
Phase of Trial
Geography
CSI specialises in supplying oncology products to clinical trials all over the world. Treatments for cancer have been advancing at an accelerated pace in recent years, resulting in significant clinical benefits and increased specificity through selection according to biomarkers or through engineered cell or gene therapies. Innovation is in our DNA, and we want to be part of your journey, helping you to advance your studies and improve patient outcomes with our clinical trial supply expertise.
Case Study
Oncology Product Batch Hunting
How CSI delivered mission impossible: sourcing specific tested batches of an expensive oncology product from several European markets
Medicine
Keytruda
(pembrolizumab
Eylea
(aflibercept)
Opdivo
(nivolumab)
Yervoy
(ipilimumab)
Jakavi
(ruxolitinib)
Number of Studies
50+
50+
50+
50+
25+
Phase of Trial
1, 2, 3
1, 2, 3
1, 2, 3
1, 2, 3
2, 3
Geography
Europe, USA
Europe, USA, Latin America
Global
Global
Global
Challenge
To supply an oncology product for a client’s trial, with a caveat: a sample from each batch had to be tested before purchasing the bulk
Outcome
CSI’s high level of market knowledge resulted in the successful delivery of the required product and ensured the client’s trial never ran dry
Solution
We worked closely with suppliers to hunt specific batches in several European markets where batch visibility and documentation were possible
We know our science
There are many different types of targeted cancer drugs. These are categorised depending on how they work. Some drugs belong to more than one group because they work in more than one way. For example, a drug that works by blocking cancer cell growth may also be a monoclonal antibody. Some of these targeted drugs might also be called immunotherapies or biological therapies.
Monoclonal Antibodies (MABs)
Monoclonal antibodies (MABs) are a type of targeted drug therapy. They work by recognising and targeting specific proteins on cancer cells. There are many different MABs to treat cancer, and they work in different ways to kill the cancer cell or stop it from growing.
Pertuzumab
a treatment for breast cancer
Bevacizumab
a treatment for a number of different cancer types
Rituximab
a treatment for chronic lymphocytic leukaemia (CLL) and some types of non-Hodgkin lymphoma
Cetuximab
a treatment for advanced bowel cancer, and head and neck cancer
Trastuzumab
used to treat breast cancer and stomach cancer
Ipilimumab and Nivolumab
used together to treat a number of different cancer types
Some MABs help the immune system to attack and kill cancer cells, so they are also a type of immunotherapy.
Cancer Growth Blockers
Cancer growth blockers are also called cancer growth inhibitors, and there are many different types. Our body makes chemicals called growth factors that control cell growth. Cancer growth blockers work by blocking the growth factors that trigger cancer cells to divide and grow.
controls cell growth
Epidermal growth factor (EGF)
controls blood vessel development
Vascular endothelial growth factor (VEGF)
controls blood vessel development and cell growth
Platelet derived endothelial growth factor (PDGF)
controls cell growth
Fibroblast growth factor (FGF)
olaparib (Lynparza)
rucaparib (Rubraca)
niraparib (Zejula)
PARP Inhibitors
PARP inhibitors can be used to treat ovarian cancer and are currently in clinical trials for treatment of other types of cancer.
PARP (poly-ADP ribose polymerase) is a protein found in our cells that helps damaged cells to repair themselves. As a cancer treatment, PARP inhibitors stop the PARP from repairing cancer cells, so the cell dies.
Olaparib
Rucaparib
Niraparib
Drugs that block blood vessel growth factor
Some anti-angiogenics prevent vascular endothelial growth factor (VEGF) from attaching to the receptors on the cells that line the blood vessels. This stops the blood vessels from growing. One drug that blocks VEGF is bevacizumab (Avastin), which is also a monoclonal antibody. It is a treatment for several different types of cancer.
Bevacizumab
Aflibercept
Ramucirumab
Anti-Angiogenics
Anti-angiogenic drugs are treatments that stop cancer tumours from growing their own blood vessels, slowing their growth and sometimes shrinking them. There are different types of anti-angiogenic drugs, which work in different ways.
Checkpoint Inhibitors
Checkpoint inhibitors are a type of immunotherapy. They are a treatment for cancers such as melanoma skin cancer and lung cancer. These drugs block different checkpoint proteins. You might also hear them named after these checkpoint proteins: CTLA-4 inhibitors, PD-1 inhibitors and PD-L1 inhibitors.
Pembrolizumab
Ipilimumab
Nivolumab
Atezolizumab
Avelumab
Advances in cancer therapeutics
Over the past five years, 61 cancer drugs, each approved in one or more tumours, have impacted the treatment of 23 different cancer types. The rise of immuno-oncology since 2014 has been largely centred on the PD-1 and PD-L1 mechanisms – so-called checkpoint inhibitors – which have broad efficacy across solid tumours and are used across 23 different tumour types.
The range of clinical benefits from this new group of medicines includes several with total remission rates above 50% and significant extensions of overall survival, as well as some with incremental survival benefits in tumours where those rates were already extremely high.
Monoclonal Antibodies (MABs)
Monoclonal antibodies (MABs) are a type of targeted drug therapy. They work by recognising and targeting specific proteins on cancer cells. There are many different MABs to treat cancer, and they work in different ways to kill the cancer cell or stop it from growing.
Pipeline for clinical development
More than 700 cancer drugs are in late-stage development – up over 60% from a decade ago. Over one third of these clinical trials are using biomarkers to stratify patients, pointing to even more personalised and effective cancer treatments in the future.
At CSI, we design supply chains to minimise wastage and ensure sites have the medication they need, precisely when they need it. We proactively manage your study’s supplies and can deliver significant savings.
Axitinib
Dasatinib
Erlotinib
Imatinib
Nilotinib
Pazopanib
Sunitinib
Bortezomib
Drugs that block signalling within the cell
Some drugs stop the VEGF receptors from sending growth signals into the blood vessel cells. These treatments are also called cancer growth blockers or tyrosine kinase inhibitors (TKIs).
Sunitinib
Sorafenib
Axitinib
Regorafenib
Cabozantinib
Get in touch with a member of our experienced team today to discuss your clinical trial supply requirements
Contact us
.png){kind=logo}